Abstract Details

Title Risk of Falls in Parkinson's Disease after Deep Brain Stimulation

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 184

Objective

Background BACKGROUND: Falls are a major source of morbidity and disability in patients with PD. Although motor function improved significantly with DBS, there were also significantly more events for falls for the DBS group vs BMT group during 6 months of follow-up. Therefore, there is a need to investigate the major risk factors associated with falling after DBS.

Design/Methods DESIGN/METHODS: Data from a randomized controlled trial comparing the 6-month outcomes for patients with PD who received DBS vs. BMT were analyzed. Multiple variables for demographics and disease symptoms of the two groups and those of the fallers and nonfallers in the DBS group were compared using statistical univariate and multivariate logistic regression analysis.

Results RESULTS: During the 6 months of follow-up, 41% or 75 of 182 subjects (men=148; mean age=61.8; mean years taking PD medications=10.6) in the DBS group fell as compared to 22 of 134 subjects (16%; men=110; mean age=62.3 years; mean years taking PD medications=12.6) in the BMT group (p<0.0001). Higher risk of falling occurred for those with DBS, older age, female gender, years since diagnosis, and living alone at baseline as well as change in the UPDRS II score at 3 months.

Conclusions CONCLUSIONS: Preventing falls is of paramount importance in the care of patients with PD. A subgroup of patients may be at a higher risk for falls after DBS. Special attention to fall risk using management plans should be implemented to avoid this potentially serious adverse event after an otherwise very beneficial treatment.

Authors/Disclosures
Eugene C. Lai, MD, PhD, FAAN (Houston Methodist Neurological Institute) PRESENTER	Dr. Lai has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
Antonios Bayas	No disclosure on file
Kenneth Follett, MD (University of Nebraska Medical Center)	Dr. Follett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic Neurological.
Matthew B. Stern, MD	Dr. Stern has received personal compensation for serving as an employee of Mediflix, Inc. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Stern has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroderm.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��